Objective: To examine the association between neuropsychiatric symptoms (NPS) with self-and caregiver-rated Quality of Life (QoL) for patients with Alzheimer's disease (AD) during a 5-year follow-up. Methods: The ALSOVA 5-year follow-up study included, at baseline, 236 patients with either very mild (Clinical Dementia Rating Scale (CDR) 0.5), or mild (CDR 1) AD, together with their caregivers from three Finnish hospital districts. QoL was evaluated using patient self-reported, and caregiver-rated, QoL in AD (QoL-AD) scores. NPS were assessed using the Neuropsychiatric Inventory (NPI), and AD severity was evaluated using the CDR, with cognition tested by the mini-mental state examination. The performance of daily activities was assessed using the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory. Results: Over the 5-year follow-up period, patient self-reported QoL-AD scores did not change significantly (p = 0.245), despite increases in their NPS. However, caregiver-rated patient QoL-AD scores declined significantly (p ≤ 0.001), as total NPI scores increased during follow-up. No NPS at baseline, and only apathy at follow-up, correlated significantly (p = 0.007) with patient self-rated QoL-AD scores. Caregiver-rated patient QoL-AD scores correlated significantly with most NPS, especially (p ≤ 0.001) apathy, agitation, anxiety, irritability, depression, and delusions at baseline, and delusions, hallucinations, apathy, appetite disturbances, and anxiety during follow-up. Conclusions: Patient rated QoL-AD scores are an unreliable tool with which to evaluate the success of therapy for NPS. Instead, caregiver-rated scores for patients correlated well with NPI scores, and health care professionals in the clinic should preferentially use these.
Introduction
Neuropsychiatric symptoms (NPS) are common, even in the early stages of Alzheimer's disease (AD) (Karttunen et al., 2011; Khoo et al., 2013) , and almost all patients with AD develop NPS at some stage of their disease (Aalten et al., 2007; Lyketsos, 2011) . The prevalence of NPS varies from 60 to 90% during the course of the disease (Youn et al., 2011; Balthazar et al., 2014) and increases with disease progression (Conde-Sala et al., 2016) .
NPS are associated with an accelerated functional decline (D'Onofrio et al., 2012) , increased morbidity, mortality, hospital stays (Wancata et al., 2003) , caregiver burden and depression, earlier institutionalization, and a significant rise in the cost of care (Gauthier et al., 2010; Vogel et al., 2010) .
The most common NPS are apathy, depression, agitation, and irritability (Vogel et al., 2010; Karttunen et al., 2011; Steinberg et al., 2014) . Agitation, irritability, anxiety (Shin et al., 2005; Huang et al., 2012; Khoo et al., 2013) , aggression (Shin et al., 2005) , sleep disorders, delusion, and hallucinations (Allegri et al., 2006; Huang et al., 2012) are among the most challenging and distressing symptoms from the caregivers' perspective.
Several cross-sectional studies based on both patient and caregiver responses have indicated that NPS affect the Quality of Life (QoL) for patients with AD (Shin et al., 2005; Matsui et al., 2006; Hurt et al., 2008; Gómez-Gallego et al., 2012) . Given the current absence of any cure for this disease, QoL, and its preservation, has become a prominent focus of attention for the medical profession (Ettema et al., 2005) .
The aims of this study were to examine the association between NPS and self-and caregiver-rated QoL scores in patients with AD at baseline, and during a 5-year follow-up period. Furthermore, we examined factors other than NPS that are associated with changes in QoL for AD patients. To the best of our knowledge, this is the first longitudinal, 5-year study to investigate the associations between NPS and selfand caregiver-rated QoL in patients with AD.
Study participants and methods

Participants
This prospective ALSOVA follow-up study included, at baseline, 236 patients with very mild (Clinical Dementia Rating Scale (CDR) 0.5) or mild (CDR 1) AD, and their caregivers, from three Finnish hospital districts. Inclusion criteria included patients aged of 65 or older, a CDR of 0.5 or 1, informed consent, community-dwelling, the absence of other life-threatening illnesses, and a family caregiver, who could be a spouse, sibling, child, or some other relative in daily contact with the patient. The endpoint of the study was either institutionalization or death. Patient participants were recruited during the first year following their diagnosis of AD, from April 2002 to September 2006. The last follow-up visits were arranged during 2011, with the last questionnaires distributed to caregivers in 2012.
A diagnosis of AD was reached according to the criteria devised by the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) (McKhann et al., 1984) , together with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (American Psychiatric Association, APA, 1994) . A geriatrician or neurologist made the initial diagnosis following referral of the patient to a memory clinic; a neurologist participating in this study then verified each diagnosis. In addition, all patients were subject to a diagnostic evaluation, including a clinical examination, brain imaging (CT or MRI), laboratory screening, and a neuropsychological examination. Patients were advised to initiate AD-targeted drug therapy at the time of their diagnosis or baseline visit.
Data collection
Each patient and their caregiver were followed up annually, for three years after an initial baseline visit, with an additional fifth-year visit. Each visits included a participation in a structured interview for both a patient and caregiver (performed by the study nurse or psychologist), and a neuropsychological evaluation of the patient conducted by a psychologist. Data collected during the study visit included age, gender, education (measured as total years of schooling), living arrangements, income, activities, and general health (other diseases, use of the drugs). The characteristics of the study population at baseline and at the time of the four follow-up visits are described in Table 1 . The study drop-out rates and reasons at each time point are presented in Supplementary Table 1. The number  of patients and observations with available data on key  variables at each study visit are presented in Supplementary Table 2 .
Measures
The Quality of Life in Alzheimer's disease scale (QoL-AD) was rated both by the patient and caregiver. This scale was developed to assess AD patient's QoL from both the patient and caregiver perspective (Logsdon et al., 1999) . The questionnaire contains 13 items: physical health, energy, mood, living situation, memory, family, marriage, friends, self as a whole, ability to do chores, ability to do things for fun, money, and life as a whole. Each item has response options ranging from 1 (poor) to 4 (excellent); these are then added to generate a summary score ranging from 13 (worst) and 52 (best). Because the data from the present study include married, widowed, and single patients, the marriage dimension was excluded from the total score in order to facilitate patient subgroup comparisons (limiting the potential score range to 12-48). In an earlier study (Hongisto et al., 2015) , we showed that the AD patient's ability to respond to QoL questionnaires deteriorated rapidly with disease progression.
We also found that the QoL-AD scale correlated slightly better with AD progression than a generic health-related QoL instrument (15D and VAS). Therefore, in the present study, we report only the QoL-AD scale.
The 12-item Neuropsychiatric Inventory (NPI) was used to assess NPS during the one month prior to the examination (Cummings et al., 1994) . NPI is an interview-based tool which evaluates the frequency and severity of delusions, hallucinations, agitation, depression, anxiety, euphoria, apathy, nighttime behavior disturbances, appetite disorders, disinhibition, irritability, and aberrant motor behavior. Each NPI item is rated on both frequency (scores from 1 to 4) and severity (scores from 1 to 3). Each item score is calculated by multiplying frequency with times severity. The total score is sum of the 12 items. Total score ranges from 0 to 144 (144 is the worst possible). The higher the total score, the more severe the symptoms. NPI total score range is classified as follows: less than 20; mild symptoms, 20 -50; moderate symptoms, The CDR was used to evaluate the severity of AD. CDR is a global assessment tool containing six domains: memory, orientation, judgment and problem solving, community affairs, homes and hobbies, and personal care (Hughes et al., 1982; Morris, 1993) . The rating is obtained through semi-structured interviews of patients and their caregivers, in which the six domains are rated on a 5-point scale: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). Six domains are then either formulated to a global rating (0, 0.5, 1, 2, 3) through a complex scoring algorithm or to a CDR-SOB score-, which is obtained by simply summing the domain ratings, ending with a continuous score ranging from 0 to 18. CDR-SOB scores have been demonstrated to correspond reliably to global scores; CDR-SOB scores from 0.5 to 4.0 correspond to a global score of 0.5; scores from 4.5 to 9.0 to a global score of 1.0; scores from 9.5 to 15.5 to a global score of 2.0; and scores from 16.0 to 18.0 to a global score of 3.0 (O'Bryant et al., 2010; Coley et al., 2011) .
The mini-mental state examination (MMSE) (Folstein et al., 1975) was used to assess the cognition. MMSE is a widely used 30-point instrument to measure cognitive ability, attention, memory, orientation, language, and visuospatial ability. The overall score ranges from 0 to 30, higher scores indicating better cognitive function.
The Alzheimer's Disease Cooperative StudyActivities of Daily Living Inventory (ADCS-ADL) was used to evaluate patients' ability to perform daily activities (Galasko et al., 1997) . It is a caregiver administered 23-item scale, which score ranges from 0 to 78 with higher scores indicating better functioning. The caregivers are asked in an interview format to rate the patient's level of performance for each activity in the past four weeks.
Ethical considerations
The ethical committee of the Kuopio University Hospital gave a favorable opinion for the ALSOVA study (the original decision N0. 64/00, the latest update 2015). Potential participants were informed about the study both orally and written, with an emphasis on the voluntary nature of participation and the confidentiality of collected data. The informed consent form was signed by both the patient and the caregiver. The caregivers also provided proxy consent on behalf of the patient.
Statistical analyses
Descriptive statistical methods (i.e., means, percentages) were used to characterize the data. We used the baseline and whole collected follow-up data in our analyses. All univariate and multivariate statistical analyses were performed using linear mixed effects model (LMM). LMM's advantage is the possibility to use of all available longitudinal data, also the data of dropouts. If conventional analysis of variance methods for repeated measurements were applied, complete data had been required on every subject (on every visit over the follow-up) or else they are dropouts from the analysis, which in turn could lead to significant loss of statistical power and a potential source of sample bias (i.e., individuals with complete data may not be representative of the entire cohort). The parameters, which were statistically significant in univariate analyses, were chosen for multivariate analysis. MMSE and ADCS-ADL measures the same features of AD, than the CDR Global Rating and also correlates strongly with CDR. Thus, we carried out two different multivariate analyses, one without MMSE and ADCS-ADL and the other without CDR. We carried out backward variable selection for multivariate model. The least significant parameters were dropped out from the model until all the coefficients are statistically significant. We set p-value under 0.05 to indicate statistical significance in results. All statistical analysis was performed with R statistical software version 3.0.2. We used R package 'nlme' in model fitting.
Results
Over the 5-year follow-up, patient self-rated QoL-AD did not change significantly (p = 0.245), when the NPI total score increased. In contrast, caregiver-rated patient QoL-AD declined significantly (p ≤ 0.001), when the NPI total score increased over the followup time (Figure 1) . Results from univariate and multivariate analysis are presented in Table 2 .
Univariate analysis (Table 3) showed that none of the NPS was associated with patient self-rated QoL-AD in baseline. During the 5-year follow-up, only apathy (p = 0.007) had effect on patient self-rated QoL-AD. However, at baseline, caregiver-rated patient QoL-AD correlated significantly with almost all the NPS, especially (p ≤ 0.001) with apathy, agitation, Figure 1 The impact of neuropsychiatric symptoms on Quality of Life scores as reported by either the patient or caregiver at each time point during the 5-year follow-up. The figure also expresses the correlation between measures which can be seen with more narrow confidence intervals. NPI = Neuropsychiatric Inventory. NPI total score (0-144), range 0-73. Curves were smoothed using the spline procedure. The grey area represents the confidence interval for the mean value. anxiety, irritability, and depression. During the 5-year follow-up, caregiver-rated patient QoL-AD correlated significantly (p ≤ 0.001) with delusions, hallucinations, apathy, and appetite disturbances. NPS increased in line with progression of AD during the 5 year follow-up time (Figure 2 and Table 4) .
In multivariate models, caregiver-rated patient QoL-AD had also statistically significant association with MMSE (p = 0.001), CDR global score (p ≤ 0.001), and caregiver age (p = 0.004). Instead, patient self-rated QoL-AD associated significantly with patient's age (p = 0.021), education years (p = 0.020), and ADCS-ADL (p = 0.004).
Discussion
In this study, we found that caregiver-rated patient QoL-AD declined significantly, when the NPI total score increased over the 5-year follow-up time. Also, most of the specific NPS correlated significantly with caregiver-rated patient QoL-AD both at baseline and during the 5-year follow-up. Instead, patient self-rated QoL-AD remained quite stable during the follow-up, despite the increasing NPS. In addition, none of the specific NPS had effect on patient self-rated QoL-AD at baseline, and the only symptom that had effect on self-rated QoL-AD during the five-year follow-up time was apathy. Discrepancies between patient and caregiver ratings also increased over 5-year follow-up.
Our findings are in line with results from previous cross-sectional studies (Shin et al., 2005; Buckley et al., 2012; Gómez-Gallego et al., 2012) and longitudinal studies by Tatsumi et al., 2009 and Conde-Sala et al., 2016 . The patients with AD suffer from anosognosia (Vogel et al., 2004; Vogel et al., 2006; Conde-Sala et al., 2014 , which might explain the fact that the self-rated QoL does not decline with disease progression and that the patient's themselves do not recognize the NPS. Some recent studies have reported that the AD patients, who lack insight, have more NPS, than patients, who are aware of their condition and deficits (Vogel et al., 2010; Conde-Sala et al., 2016) . We also found in our recent study (Hongisto et al., 2015) that the ability to respond to questionnaires unassisted or even assisted diminish at an early moderate stage of AD. On the other hand, persons with AD may find their QoL good in spite of the AD, if they are satisfied with their physical health, the relationship with children, or marriage, for example (Ready et al., 2004; Trigg et al., 2011; Trigg et al., 2015) . In our study, NPS increased with progression of AD, that finding is supported by previous studies (Khoo et al., 2013; Conde-Sala et al., 2016) . Clinically significant NPS have been found to be predictive of faster progression to severe AD dementia and death (Peters et al., 2015) . The early diagnosis of AD and early start of AD-targeted medication seem to prevent development of severe NPS (Wynn and Cummings, 2004; Rodda et al., 2009; Hallikainen et al., 2013) . Many studies have also shown that AD-related NPS leads to increasing burden on their caregivers (Agüera-Ortiz et al., 2010; Mohamed et al., 2010; Vogel et al., 2010; Khoo et al., 2013; Turro-Turró-Garriga et al., 2013; Välimäki et al., 2015) and increases the risk of premature institutionalization (Gauthier et al., 2010; Gaugler et al., 2011) . Again, caregivers may also reflect their own feelings of burden, when they evaluate NPS severity or the QoL of the patients (Black et al., 2012; Gómez-Gallego et al., 2012; Andrieu et al., 2016) . On the other hand, caregivers may also have difficulties to identify the patients NPS especially in mild AD (Stella et al., 2015) . Thus, it is important that clinicians become aware of NPS in patients with AD and improve the early detection of NPS by asking about the patient's behavior more detailed using structured and validated questionnaires. Based on our findings, it seems apparent that, patient self-rated QoL-AD cannot be recommended to use in evaluation of the effect of NPS in patients QoL or as a measure of successful treatment of the NPS. Instead, caregivers are well aware of patients QoL and that knowledge health care professionals should use more in clinical practice.
We also examined which other factors are associated with the changes in AD patients QoL during the 5-year follow-up time. Patients self-reported QoL decline with higher age, lower level of education, and functional loss in activities of daily living. However, caregivers' ratings of patients QoL seemed to decline with a lower level of cognitive function, increased NPS, severity of AD, and caregivers' higher age.
In the previous 3-year follow-up study by Vogel et al. (2012) , they found that caregiver rated patientQoL decline with changes in patient's activities of daily living (ADCS-ADL). Three-year follow-up study by Conde-Sala et al. (2014) identified that male gender and higher level of education and anosognosia were associated with higher patient's self-rated QoL, while depression associated with lower patients' self-rated QoL. Instead, caregiver rated patient QoL was significantly influenced by patient's functional status and NPS. This finding is supported by Tatsumi et al. (2009) in a 2-year follow-up study. Buckley et al. (2012) found in previous cross-sectional study that comorbidity was associated with lower self-reported QoL, whereas NPS influenced negatively caregiver-rated patient QoL.
The present study has several strengths. The main strength is well-designed clinical setting and careful diagnostic evaluation of participants. All the patients were community-dwelling and treated with according standard care, which reduces the bias. We also examine the patient QoL by asking both self-and caregiver-rated QoL-AD. In addition, our study involves the longest QoL follow-up (5-year) data so far and has a homogeneous patient group with very mild or mild AD at baseline. The main limitation of the study is the fact, that quite a large proportion of the patients were not able to participate all the followups during the 5-year follow-up period as expected in this age group. The patients who did not remain in the study for the full 5-year period had at baseline lower cognition and lower ADCS-ADL and their caregivers had more depressive symptoms. The drop-out rate in this study is in line with those observed in previous comparable studies (Conde-Sala et al., 2014; Missotten et al., 2007; Phung et al., 2013) . Dropouts may lead to bias in statistical analyses and may influence the results. To avoid the bias as much as possible, we used LMM in the statistical analyses. LMM have an advantage compared to more conventional methods, because all available longitudinal data, also the data of dropouts, is possible to use in the analyses.
Conclusion
Patient self-rated QoL-AD remained quite stable during the 5-year follow-up time, despite the increasing NPS. However, caregiver-rated patient QoL-AD declined significantly, when the NPS increased with progression of AD during the follow-up. Furthermore, almost all the specific NPS associated significantly with caregiverrated patient QoL-AD. We cannot recommend to use patient self-rated QoL-AD as a measure of successful treatment of the NPS or as a measure of the effect of NPS to AD patients QoL. Instead, caregivers are well aware of patients QoL and that knowledge health care professionals should use more in clinical practice.
Key points:
• During the 5-year follow-up, patient rated QoL-AD scores remained relatively stable, irrespective of the severity of their neuropsychiatric symptoms
• Caregiver-rated patient QoL-ADs declined significantly, in line with an increase in total NPI scores during the follow-up period. Discrepancies between patient and caregiver ratings also increased over the 5-year follow-up.
• Apathy was the only neuropsychiatric symptom to correlate with patient reported QoL-AD scores during follow-up; no correlates between neuropsychiatric symptoms and patient reported QoL-ADs were reported at baseline.
• Caregiver-rated QoL-AD scores for patients correlated significantly with the majority of neuropsychiatric symptoms, especially apathy, agitation, anxiety, irritability, depression, and delusions at baseline, and delusions, hallucinations, apathy, appetite disturbances, and anxiety during the 5-year follow-up.
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